BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn’s disease are associated with the clinical course of the disease. World J Gastroenterol 2008; 14(1): 85-89 [PMID: 18176967 DOI: 10.3748/wjg.14.85] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Kälsch AI, Csernok E, Münch D, Birck R, Yard BA, Gross W, Kälsch T, Schmitt WH. Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol 2010;37:2319-25. [PMID: 20716656 DOI: 10.3899/jrheum.100302] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
2 Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T. Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria. Intest Res 2019;17:340-8. [PMID: 31129948 DOI: 10.5217/ir.2019.00012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, Kasirer Y, Muise A, Seow CH, Silverberg MS, Crandall W, Griffiths AM. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? J Crohns Colitis. 2011;5:423-429. [PMID: 21939916 DOI: 10.1016/j.crohns.2011.05.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
4 Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis 2013;7:e263-70. [PMID: 23182164 DOI: 10.1016/j.crohns.2012.10.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
5 Kwak MS, Kim DH, Park SJ, Kim TI, Hong SP, Kim WH, Cheon JH. Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol. 2014;14:85. [PMID: 24886458 DOI: 10.1186/1471-230x-14-85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kwak MS, Kim KJ, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Elevated C-reactive protein is associated with disease progression in patients with mild Crohn's disease. Springerplus 2016;5:878. [PMID: 27386326 DOI: 10.1186/s40064-016-2606-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2011;46:420-7. [PMID: 21114432 DOI: 10.3109/00365521.2010.539253] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
8 Alrefai D, Jones J, El-Matary W, Whiting SJ, Aljebreen A, Mirhosseini N, Vatanparast H. The Association of Vitamin D Status with Disease Activity in a Cohort of Crohn's Disease Patients in Canada. Nutrients 2017;9:E1112. [PMID: 29023388 DOI: 10.3390/nu9101112] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zhu Y, Xu H, Liu W, Qi W, Yang X, Ye L, Cao Q, Zhou W. Glasgow prognostic score is a practical predictive index for postoperative intra-abdominal septic complications after bowel resection in Crohn's disease patients. Int J Colorectal Dis 2018;33:947-53. [PMID: 29687374 DOI: 10.1007/s00384-018-3035-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
10 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Reference Citation Analysis]
11 Silva AFD, Schieferdecker MEM, Rocco CS, Amarante HMBDS. Relação entre estado nutricional e atividade inflamatória em pacientes com doença inflamatória intestinal. ABCD, arq bras cir dig 2010;23:154-8. [DOI: 10.1590/s0102-67202010000300005] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Iaculli E, Agostini M, Biancone L, Fiorani C, Di Vizia A, Montagnese F, Sibio S, Manzelli A, Tesauro M, Rufini A, Sica GS. C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease. Cell Death Discov. 2016;2:16032. [PMID: 27551522 DOI: 10.1038/cddiscovery.2016.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806-1816. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
14 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 31.0] [Reference Citation Analysis]
15 Khanna R, Narula N, Feagan BG. The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1619-23. [PMID: 29846593 DOI: 10.1093/ibd/izy195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
17 Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, D'haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel J, Panaccione R. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013;7:653-69. [DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
18 Kwon JH, Im JP, Ye BD, Cheon JH, Jang HJ, Lee KM, Kim YS, Kim SW, Kim YH, Song GA, Han DS, Kim WH, Kim JS. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. Gut Liver 2016;10:595-603. [PMID: 27021506 DOI: 10.5009/gnl15411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
19 Moscandrew ME, Loftus EV. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Curr Gastroenterol Rep 2009;11:488-95. [DOI: 10.1007/s11894-009-0074-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
20 Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1239-1246. [PMID: 20127998 DOI: 10.1002/ibd.21212] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
21 Abraham BP, Thirumurthi S. Clinical significance of inflammatory markers. Curr Gastroenterol Rep 2009;11:360-7. [PMID: 19765363 DOI: 10.1007/s11894-009-0055-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Wu T, Ji G. Abnormal glucose, lipid and protein metabolism in patients with Crohn's disease. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 160-168 [DOI: 10.11569/wcjd.v18.i2.160] [Reference Citation Analysis]
23 Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, Sujino T, Miyoshi J, Takabayashi K, Mikami Y, Mizuno S, Wada Y, Yajima T, Naganuma M, Inoue N, Iwao Y, Ogata H, Hasegawa H, Kitagawa Y, Hibi T, Kanai T. Risk and Management of Intra-Abdominal Abscess in Crohn's Disease Treated with Infliximab. Digestion 2014;89:201-8. [DOI: 10.1159/000360618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
24 Musci JO, Cornish JS, Däbritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 2016;51:531-47. [PMID: 26975751 DOI: 10.1007/s00535-016-1191-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
25 Edlund H, Grisic A, Steenholdt C, Ainsworth MA, Brynskov J, Huisinga W, Kloft C. Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. Therapeutic Drug Monitoring 2019;41:235-42. [DOI: 10.1097/ftd.0000000000000590] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Mosli M, Saeedi A, Alnefaie M, Bawahab N, Abdo L, Shobai S, Alsahafi M, Saadah O. Awareness and cognition of illness in Saudi Arabian patients with Crohn's disease. Saudi J Gastroenterol 2021;27:91-6. [PMID: 33723091 DOI: 10.4103/sjg.SJG_371_20] [Reference Citation Analysis]
27 Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129-136. [PMID: 23932786 DOI: 10.1016/j.crohns.2013.07.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
28 Magro F, Sousa P, Ministro P. C-reactive protein in Crohn's disease: how informative is it? Expert Rev Gastroenterol Hepatol. 2014;8:393-408. [PMID: 24635486 DOI: 10.1586/17474124.2014.893821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
29 Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol 2015;15:103. [PMID: 26271624 DOI: 10.1186/s12876-015-0333-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
30 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
31 Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin–biroulet L, Colombel J, Hanauer SB, Sandborn WJ. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology 2015;13:1042-1050.e2. [DOI: 10.1016/j.cgh.2013.09.006] [Cited by in Crossref: 163] [Cited by in F6Publishing: 143] [Article Influence: 23.3] [Reference Citation Analysis]
32 Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009;104:2768-2773. [PMID: 19672253 DOI: 10.1038/ajg.2009.454] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
33 Iborra M, Beltrán B, Nos P. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:641-56. [PMID: 27633593 DOI: 10.1016/j.giec.2016.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]